Cargando…
Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards
Molecular tumor boards (MTBs) require specialized activities to leverage genomic data for therapeutic decision-making. Currently, there are no defined standards for implementing, executing, and tracking the impact of MTBs. This study describes the development and validation of ACTE-MTB, a tool to ev...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106161/ https://www.ncbi.nlm.nih.gov/pubmed/35560035 http://dx.doi.org/10.1371/journal.pone.0268477 |
_version_ | 1784708216607735808 |
---|---|
author | Love, Tara M. Anaya, Daniel A. Prime, Matthew S. Ardolino, Luke Ekinci, Okan |
author_facet | Love, Tara M. Anaya, Daniel A. Prime, Matthew S. Ardolino, Luke Ekinci, Okan |
author_sort | Love, Tara M. |
collection | PubMed |
description | Molecular tumor boards (MTBs) require specialized activities to leverage genomic data for therapeutic decision-making. Currently, there are no defined standards for implementing, executing, and tracking the impact of MTBs. This study describes the development and validation of ACTE-MTB, a tool to evaluate the maturity of an organization’s MTB to identify specific areas that would benefit from process improvements and standardization. The ACTE-MTB maturity assessment tool is composed of 3 elements: 1) The ACTE-MTB maturity model; 2) a 59-question survey on MTB processes and challenges; and 3) a 5-level MTB maturity scoring algorithm. This tool was developed to measure MTB maturity in the categories of Access, Consultation, Technology, and Evidence (ACTE) and was tested on 20 MTBs spanning the United States, Europe, and Asia-Pacific regions. Validity testing revealed that the average maturity score was 3.3 out of 5 (+/- 0.1; range 2.0–4.3) with MTBs in academic institutions showing significantly higher overall maturity levels than in non-academic institutions (3.7 +/- 0.2 vs. 3.1 +/- 0.2; P = .018). While maturity scores for academic institutions were higher for Consultation, Technology, and Evidence domains, the maturity score for the Access domain did not significantly differ between the two groups, highlighting a disconnect between MTB operations and the downstream impact on ability to access testing and/or therapies. To our knowledge, ACTE-MTB is the first tool of its kind to enable structured, maturity assessment of MTBs in a universally-applicable manner. In the process of establishing construct validity of this tool, opportunities for further investigation and improvements were identified that address the key functional areas of MTBs that would likely benefit from standardization and best practice recommendations. We believe a unified approach to assessment of MTB maturity will help to identify areas for improvement at both the organizational and system level. |
format | Online Article Text |
id | pubmed-9106161 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-91061612022-05-14 Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards Love, Tara M. Anaya, Daniel A. Prime, Matthew S. Ardolino, Luke Ekinci, Okan PLoS One Research Article Molecular tumor boards (MTBs) require specialized activities to leverage genomic data for therapeutic decision-making. Currently, there are no defined standards for implementing, executing, and tracking the impact of MTBs. This study describes the development and validation of ACTE-MTB, a tool to evaluate the maturity of an organization’s MTB to identify specific areas that would benefit from process improvements and standardization. The ACTE-MTB maturity assessment tool is composed of 3 elements: 1) The ACTE-MTB maturity model; 2) a 59-question survey on MTB processes and challenges; and 3) a 5-level MTB maturity scoring algorithm. This tool was developed to measure MTB maturity in the categories of Access, Consultation, Technology, and Evidence (ACTE) and was tested on 20 MTBs spanning the United States, Europe, and Asia-Pacific regions. Validity testing revealed that the average maturity score was 3.3 out of 5 (+/- 0.1; range 2.0–4.3) with MTBs in academic institutions showing significantly higher overall maturity levels than in non-academic institutions (3.7 +/- 0.2 vs. 3.1 +/- 0.2; P = .018). While maturity scores for academic institutions were higher for Consultation, Technology, and Evidence domains, the maturity score for the Access domain did not significantly differ between the two groups, highlighting a disconnect between MTB operations and the downstream impact on ability to access testing and/or therapies. To our knowledge, ACTE-MTB is the first tool of its kind to enable structured, maturity assessment of MTBs in a universally-applicable manner. In the process of establishing construct validity of this tool, opportunities for further investigation and improvements were identified that address the key functional areas of MTBs that would likely benefit from standardization and best practice recommendations. We believe a unified approach to assessment of MTB maturity will help to identify areas for improvement at both the organizational and system level. Public Library of Science 2022-05-13 /pmc/articles/PMC9106161/ /pubmed/35560035 http://dx.doi.org/10.1371/journal.pone.0268477 Text en © 2022 Love et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Love, Tara M. Anaya, Daniel A. Prime, Matthew S. Ardolino, Luke Ekinci, Okan Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards |
title | Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards |
title_full | Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards |
title_fullStr | Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards |
title_full_unstemmed | Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards |
title_short | Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards |
title_sort | development and validation of acte-mtb: a tool to systematically assess the maturity of molecular tumor boards |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106161/ https://www.ncbi.nlm.nih.gov/pubmed/35560035 http://dx.doi.org/10.1371/journal.pone.0268477 |
work_keys_str_mv | AT lovetaram developmentandvalidationofactemtbatooltosystematicallyassessthematurityofmoleculartumorboards AT anayadaniela developmentandvalidationofactemtbatooltosystematicallyassessthematurityofmoleculartumorboards AT primematthews developmentandvalidationofactemtbatooltosystematicallyassessthematurityofmoleculartumorboards AT ardolinoluke developmentandvalidationofactemtbatooltosystematicallyassessthematurityofmoleculartumorboards AT ekinciokan developmentandvalidationofactemtbatooltosystematicallyassessthematurityofmoleculartumorboards |